Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has said it is delaying finalizing regulatory guidelines for lab-developed tests (LDTs), but people closely following the decades-long controversy believe that the draft document released two years ago is dead in the current political climate.

This is welcome news for those in the lab industry that have fought the FDA's every attempt, over more than 20 years, to regulate LDTs under the device law.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.